Tengshengbo Pharmaceutical announces that the combination therapy of ambavirumab/romisvirimab maintains the neutralizing activity against the new coronavirus mutant strain "Omi Keron"

The experimental data of the in vitro chimeric virus against "Omi Keron" shows that the combination therapy of Ambavirimab/Romisvirimab is maintained against "Omi Keron" and other new coronavirus variants that have received widespread attention.

Beijing, China and Durham, North Carolina, USA, December 12, 2021/PRNewswire/ - Brii Biosciences (hereinafter referred to as "Tengsheng Biopharma" or "Company", stock code) : 2137.

These data add more evidence to prove that the combination therapy of ambavirumab/romisvirimab maintains activity against the major new coronavirus pneumonia virus variants that the World Health Organization (WHO) is concerned about, including B.

Dr.

The test data of in vitro chimeric virus experiments by independent laboratories show that the "Omi Keron" variant strain is easily neutralized by the combination therapy of ambavirumab/rotamisvirumab

David Margolis, Vice President of Tengshengbo Pharmaceutical and Head of Infectious Disease Treatment, said: "These new preclinical data provide further evidence that the ambasavirzumab/romisvirzumab combination therapy is an infectious disease.

The FDA is currently reviewing the emergency use authorization (EUA) application for Ambasavirzumab/Romisvirzumab combination therapy of Tengshengbo

About Ambavir Mab/Romisvir Mab (previously known as BRII-196/BRII-198)

Ambavirimab and Romisvirizumab are non-competitive new severe acute respiratory infections obtained by Tengshengbo Pharmaceutical from Shenzhen Third People’s Hospital and Tsinghua University during the convalescent period of new coronavirus pneumonia (COVID-19).

In December 2021, the Ambasavirzumab/Romisvirzumab combination therapy was approved by the China National Medical Products Administration (NMPA) for the treatment of mild and common types with progression to severe (including hospitalization or death) ) Adults and adolescents (12-17 years old, weight ≥40 kg) with high-risk factors, patients with novel coronavirus infection (COVID-19)

In October 2021, Tengshengbo Pharmaceutical completed the submission of an emergency use authorization (EUA) application to the U.

In addition, Tengshengbo Pharmaceutical is actively advancing the registration application of ambavirumab/romisvirimab combination therapy in other mature and emerging markets around the world, first to ensure that there is a huge presence in countries that have conducted clinical trials and have access to highly effective treatments.

About Tengshengbo Pharmaceutical

Tengsheng Bo Yao Biotechnology Co.

Source: Tengsheng Boyao Biotechnology Co.